Novel Cell-free Sclerostin/LRP Binding Assay Ideal for Primary Inhibitor Screens.

• High sensitivity chemiluminescent readout (signal-to-noise ratio of ≥10)
• Rapid protocol yields results in just 2,5 hours
• No cell lines or transfection reagents required
• Reproducible, high-throughput amenable assay (Z’-factor 0.871)
• Amenable for high-throughput screening applications

The LEADING LIGHT® Sclerostin Screening System is a 1 x 96 well plate assay based on Sclerostin–LRP interaction. This system contains engineered LRP5-alkaline phosphatase (ALP) and human Sclerostin immobilized in a multi-well plate. LRP5-alkaline phosphatase binds to Sclerostin coated on the bottom of the well and is detected by the activity of alkaline phosphatase remaining after a washing step. This system can be used for drug screening to identify small molecule compounds, antibodies, DNA aptamers and peptides capable of modulating sclerostin-LRP interaction.